Applied DNA Sciences (APDN) Misses Q4 EPS by 1c

Applied DNA Sciences (NASDAQ: APDN) reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $1.79 million.

Excluding non-cash expenses, Adjusted EBITDA for the quarter ended September 30, 2016 was negative $1.7 million compared to a positive Adjusted EBITDA of $213 thousand for the same quarter last year and a negative Adjusted EBITDA of $2.6 million in the prior fiscal quarter.

For earnings history and earnings-related data on Applied DNA Sciences (APDN) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Apollo agrees to buy EasyJet Plc. (EZJ:LN) (ESYJY); Bernstein SocGen shares investment implications
• FDA approves Padcev plus Keytruda for muscle-invasive bladder cancer